**Patient Report** 

**Specimen ID:** 169-165-3772-0 **Control ID:** MCM04562100

**Acct #:** 04562100 **Phone:** (909) 391-3423 **Rte:** 00

ZAPATA, CARLOS

3303 S ARCHIBALD APT 369 ONTARIO CA 91761 (909) 708-5576 Clinica Las Palmas 527 N Palm Ave Ste 106 ONTARIO CA 91762

**Patient Details** 

**DOB:** 01/11/1967 **Age(y/m/d):** 053/05/06

Gender: M Patient ID: **Specimen Details** 

**Date collected:** 06/17/2020 1716 Local

Date received: 06/18/2020
Date entered: 06/18/2020
Date reported: 06/19/2020 2135 ET

Physician Details Ordering: | LOPEZ

Referring: ID:

**NPI:** 1538240908

**General Comments & Additional Information** 

Total Volume: Not Provided Fasting: No

Ordered Items SARS-CoV-2, NAA

TESTS RESULT FLAG UNITS REFERENCE INTERVAL LAB

SARS-CoV-2, NAA

Not Detected

Not Detected

01

Testing was performed using the Aptima SARS-CoV-2 assay. This test was developed and its performance characteristics determined by LabCorp Laboratories. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

01 CETWE LabCorp Phoenix

5005 S 40th St, Phoenix, AZ 85040-2969

Dir: Earle Collum, MD

For inquiries, the physician may contact Branch: 800-859-6046 Lab: 800-788-9743